Movement Alert｜BIOCYTOGEN-B Falls 7.83% in Regular Trading, Innovative Drug Sector Retreats as Profit-Taking Continues

Market Focus08-17

On August 17, BIOCYTOGEN-B fell 7.83% in regular trading, trading at 63.55 HKD/share, with turnover of HKD 240 million. The stock was among the biggest decliners on the Hong Kong exchange despite the Hang Seng Index rising 1.61% on the day.

The decline appears driven by continued profit-taking in the innovative drug sector following a sharp rally. The broader creative drug and CXO sector experienced a pullback late last week, with innovative drug ETFs collectively retreating. BIOCYTOGEN-B had surged from approximately 52 HKD in late July to above 70 HKD by mid-August, fueled by a strong H1 earnings preview showing net profit growth of 392%-413%, multiple institutional accumulations by E Fund and Fullgoal Fund, and a global strategic partnership with Whitehawk Therapeutics on bispecific ADC development. Within the Biotechnology sector, AKESO fell 5.83%, while INNOVENT BIO rose 1.76%, BEONE MEDICINES rose 1.14%, 3SBIO fell 0.34%, and REMEGEN fell 0.06%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157928873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 15:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157928873","market":"us","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Falls 7.83% in Regular Trading, Innovative Drug Sector Retreats as Profit-Taking Continues","media":"Market Focus","content":"<p><p>On August 17, BIOCYTOGEN-B fell 7.83% in regular trading, trading at 63.55 HKD/share, with turnover of HKD 240 million. The stock was among the biggest decliners on the Hong Kong exchange despite the Hang Seng Index rising 1.61% on the day.</p><p>The decline appears driven by continued profit-taking in the innovative drug sector following a sharp rally. The broader creative drug and CXO sector experienced a pullback late last week, with innovative drug ETFs collectively retreating. BIOCYTOGEN-B had surged from approximately 52 HKD in late July to above 70 HKD by mid-August, fueled by a strong H1 earnings preview showing net profit growth of 392%-413%, multiple institutional accumulations by E Fund and Fullgoal Fund, and a global strategic partnership with Whitehawk Therapeutics on bispecific ADC development. Within the Biotechnology sector, AKESO fell 5.83%, while INNOVENT BIO rose 1.76%, BEONE MEDICINES rose 1.14%, 3SBIO fell 0.34%, and REMEGEN fell 0.06%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Falls 7.83% in Regular Trading, Innovative Drug Sector Retreats as Profit-Taking Continues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Falls 7.83% in Regular Trading, Innovative Drug Sector Retreats as Profit-Taking Continues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-17 15:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 17, BIOCYTOGEN-B fell 7.83% in regular trading, trading at 63.55 HKD/share, with turnover of HKD 240 million. The stock was among the biggest decliners on the Hong Kong exchange despite the Hang Seng Index rising 1.61% on the day.</p><p>The decline appears driven by continued profit-taking in the innovative drug sector following a sharp rally. The broader creative drug and CXO sector experienced a pullback late last week, with innovative drug ETFs collectively retreating. BIOCYTOGEN-B had surged from approximately 52 HKD in late July to above 70 HKD by mid-August, fueled by a strong H1 earnings preview showing net profit growth of 392%-413%, multiple institutional accumulations by E Fund and Fullgoal Fund, and a global strategic partnership with Whitehawk Therapeutics on bispecific ADC development. Within the Biotechnology sector, AKESO fell 5.83%, while INNOVENT BIO rose 1.76%, BEONE MEDICINES rose 1.14%, 3SBIO fell 0.34%, and REMEGEN fell 0.06%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1157928873","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157928873","pubTimestamp":1786952355,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 17, BIOCYTOGEN-B fell 7.83% in regular trading, trading at 63.55 HKD/share, with turnover of HKD 240 million. The stock was among the biggest decliners on the Hong Kong exchange despite the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势预警|BIOCYTOGEN-B常规交易跌7.83% 创新药板块获利回吐持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On August 17, BIOCYTOGEN-B fell 7.83% in regular trading, trading at 63.55 HKD/share, with turnover of HKD 240 million. The stock was among the biggest decliners on the Hong Kong exchange despite the Hang Seng Index rising 1.61% on the day.The decline appears driven by continued profit-taking in the innovative drug sector following a sharp rally. The broader creative drug and CXO sector experienced a pullback late last week, with innovative drug ETFs collectively retreating. BIOCYTOGEN-B had surged from approximately 52 HKD in late July to above 70 HKD by mid-August, fueled by a strong H1 earnings preview showing net profit growth of 392%-413%, multiple institutional accumulations by E Fund and Fullgoal Fund, and a global strategic partnership with Whitehawk Therapeutics on bispecific ADC development. Within the Biotechnology sector, AKESO fell 5.83%, while INNOVENT BIO rose 1.76%, BEONE MEDICINES rose 1.14%, 3SBIO fell 0.34%, and REMEGEN fell 0.06%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157928873","isCrawlerRequest":true}